Samiullah Seddiqi

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

Nguyen H. Tran, V. Libri, G. Screaton, 2021, The Lancet.

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2021, The Lancet.

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Nguyen H. Tran, Vidyashankara G. Iyer, Andreas C. Themistocleous, 2020, Lancet.

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial.

Nguyen H. Tran, Andreas C. Themistocleous, David J. Smith, 2020, Lancet.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

J. Todd, P. Simmonds, C. Fraser, 2021, Nature Communications.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

J. Todd, P. Simmonds, C. Fraser, 2021, Nature Communications.